The US Food and Drug Administration has issued an "approvable letter "related to the New Drug Application for Miami, USA-based Noven Pharmaceuticals' Stavzor (delayed-release valproic acid) capsules in 125mg, 250mg and 500mg strengths. This is for the use of the drug in the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.
The FDA states in the letter that it has completed its review of the Stavzor NDA and has requested certain non-clinical information, including additional in vitro dissolution data, as a condition to final approval. The agency has not requested additional human studies or clinical data, says Noven.
Because the NDA for Stavzor references Abbott Laboratories' Depakote (valproic acid), final approval is also subject to the expiration of any applicable exclusivity periods benefiting the latter. Based on receipt of the approvable letter, interaction with Banner Pharmacaps (the NDA holder and developer of the product), and its understanding of Depakote exclusivity, Noven says it continues to expect Stavzor final approval, at the latest, by the end of July 2008.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze